Trimethoprim-sulfamethoxazole therapy did not reduce time to death, lung transplant, or hospitalization in patients with moderate or severe idiopathic pulmonary fibrosis.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.
A multidisciplinary committee of international experts have released a new clinical practice guideline on the diagnosis of adult hypersensitivity pneumonitis, an immune-mediated inflammatory lung and small airway disease.
A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.
Crisaborole was found to be safe and efficacious for treatment in patients with mild to moderate atopic dermatitis.
Clinicians should use caution when interpreting the guidelines for the diagnosis and detection of sarcoidosis and must consider unique individual clinical circumstances when managing these patients.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Treatment with nintedanib was associated with slowing the rate of forced vital capacity decline in patients with progressive fibrosing interstitial lung diseases.
In patients with sarcoidosis, cancer was found to develop earlier in men vs women.
